New ASMI Complementary Medicines Post to Tackle Growth Hurdles
22 April 2013 - The Australian Self Medication Industry (ASMI) is ramping up its capability to meet the needs of the complementary medicines (CM) industry, with a new senior appointment to oversee the strategic direction of the sector.
ASMI Executive Director, Dr Deon Schoombie, today announced the appointment of Ms Brenda Davy to the newly created position of CM Strategy Manager, responsible for managing a range of strategic issues impacting the sector across the commercial, regulatory and consumer areas.
Ms Davy brings more than 20 years' experience in management and strategic consulting roles in Australia, New Zealand, Canada and Asia, including recent experience as Global Category Marketing Manager at Blackmores and previously as Regional Marketing Director at Procter & Gamble.
Dr Schoombie said the appointment reflects the unique demands being placed on the sector as it manages exceptional growth and calls for tighter regulatory controls.
"The place of complementary medicines has never been so great, but at the same time, there is a level of scrutiny that is proving a significant challenge to firms and the industry, more generally.
"With this appointment, we are aiming to fill a need in the market for a strategic direction that can help to build a sustainable, evidence-based sector that has the trust and respect of all stakeholders, and most importantly, consumers.
"For ASMI, we recognise the need to add to our existing strengths to address what is certain to be an ongoing series of challenges facing the sector as the popularity and awareness of CMs continues to grow. I am delighted that we have someone with Brenda's extensive background and experience to join the ASMI team at this critical time."
Commenting on her appointment, Ms Davy said: "I am delighted to be taking up this exciting role at a most important time for the complementary medicines sector. Consumers and a growing number of practitioners have demonstrated their commitment to using complementary medicines. We need to work with all stakeholders to ensure a growing and profitable sector, and one in which consumers can have the utmost confidence."